Access Pharmaceuticals, Inc. (ACCP.OB) Highlights Positive Results from Oncology Product Presentation

QualityStocks would like to highlight Access Pharmaceuticals (OTCBB: ACCP), an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. The company’s products include ProLindac™, which is currently in phase II clinical testing of patients with ovarian cancer, and MuGard™ for the management of patients with mucositis.

In the company’s news yesterday,

Access Pharmaceuticals announced highlights from a poster presentation of MuGard at this year’s European Society of Medical Oncology Conference in Milan, Italy. Access CEO Jeffery Davis said the results reflect MuGuard as a valuable therapeutic option for the treatment and prevention of oral mucositis (OM), a side effect of raio/chemotherapy.

“These additional findings out of Europe are very exciting and strengthen our belief in the clinical benefits that MuGard can provide patients undergoing radiation and chemotherapy,” Davis stated in the press release. “This data confirms the competitive advantages of MuGard over the current treatment options on the market and we will use this data to educate patients, clinicians and the medical industry on the superior attributes of our product.”

The presentation noted MuGuard’s clinical experience, including:

• MuGard’s ability to provide significant improvement and/or stabilization of oral mucositis lesions and symptoms of oral mucositis (OM) in more than 75% of cancer patients treated with radiotherapy/chemotherapy;

• A 52 percent reduction in oral discomfort (oral pain and swallowing ability) in patients with pre-existing lesions of OM, and reported a substantial reduction in the use of pain medication;

• MuGard’s ready-to-use formulation was well accepted by 86 percent of patients involved in this assessment program;

• No MuGard-related adverse reactions were identified in the clinical practice.

Earlier this year, Access Pharmacueticals presented its MuGard data and clinical experience at the Multinational Association of Supportive Care in Cancer (MASSC Conference), showcasing data from a clinical trial for treatment of head and neck cancer with positive results of MuGard for oral mucositis prevention.

About QualityStocks

QualityStocks, based in Scottsdale, Arizona is a free service that collects data from hundreds Small-Cap and Micro-Cap online Investment Newsletters into one Free Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their advertising efforts and now has over 750,000+ subscribers that receive The Daily Stock Newsletters.

To sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net

Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net

Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.